Vogenx, Inc. (Ticker: VOGX US) is an American biotechnology company developing medicines for hormone-related and metabolic conditions, particularly low blood sugar after bariatric surgery and gastroparesis, a condition that slows digestion. Incorporated in Delaware and based in Raleigh, North Carolina, the company has not generated revenue.

Vogenx plans to list on Nasdaq on August 6, 2026. It is offering 6.25 million shares at an expected price range of $11.00 to $13.00 per share, seeking to raise approximately $75 million. Its estimated market capitalization at the offering is approximately $167 million.

The company’s lead drug candidate, mizagliflozin, is a pill being tested in a Phase 2b study for post-bariatric hypoglycemia, which causes blood sugar to fall too low after weight-loss surgery. Vogenx licensed most worldwide rights to the drug from Kissei Pharmaceutical, excluding Japan, Korea and Taiwan. It also plans to study mizagliflozin in gastroparesis and a rare form of Cushing’s syndrome, subject to funding and regulatory approval. JonesTrading is managing the offering.